Fluoxetine protects neurons against microglial activation-mediated neurotoxicity

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Zhang, Feng ^a,b   Zhou, Hui ^a   Wilson, Belinda C ^a   Shi, Jing Shan ^b   Hong, Jau Shyong ^a   Gao, Hui Ming ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Anti inflammation; Fluoxetine; Microglia; Neuroinflammation; Neuroprotection

Indexed keywords

FLUOXETINE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; 1 METHYL 4 PHENYLPYRIDINIUM; CYTOTOXIC FACTOR; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENANTIOMER; FEMALE; IN VITRO STUDY; INTRACELLULAR SIGNALING; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; TRANSCRIPTION TERMINATION; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN CELL CULTURE; BRAIN NERVE CELL; DEGENERATIVE DISEASE; ENANTIOMERIC RATIO; MESENCEPHALON; MICROGLIA; MICROGLIAL CELL CULTURE; SIGNAL TRANSDUCTION;

EID: 84863337793     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70066-9     Document Type: Article

References (20)

1. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-91.
2. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008;29:357-65.
3. Przedborski S. Inflammation and Parkinson's disease pathogenesis. Mov Disord 2010;25(Suppl 1):S55-7.
4. Wong DT, Perry KW, Bymaster FP. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 2005;4:764-74.
5. Chang YC, Tzeng SF, Yu L, Huang AM, Lee HT, Huang CC, et al. Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups. Neurobiol Dis 2006;24:101-13.
6. Li IH, Huang WS, Shiue CY, Huang YY, Liu RS, Chyueh SC, et al. Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET. Neuroimage 2010;49: 1259-70.
7. Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 2009;1281:108-16.
8. Chen SJ, Kao CL, Chang YL, Yen CJ, Shui JW, Chien CS, et al. Antidepressant administration modulates neural stem cell survival and serotoninergic differentiation through bcl-2. Curr Neurovasc Res 2007;4:19-29.
9. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009;87:1037-45.
10. Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, et al. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci 2002;22:3673-82.
11. Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000;293:607-17.
12. Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidasederived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 2003;17:1954-6.
13. Tan AS, Berridge MV. Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Methods 2000;238:59-68.
14. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011;60:963-74.
15. Wu DC, Re DB, Nagai M, Ischiropoulos H, Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci U S A 2006;103:12132-7.
16. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 2003;100:5473-8.
17. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide (LPS)-stimulated microglial cells. Neuropharmacology 2011.
18. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-224.
19. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A 1997;94:7531-6.
20. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2007;104:18754-9.